Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study

BACKGROUND: We previously reported that biofilms and innate immunity contribute to the pathogenesis of Kawasaki disease. Therefore, we aimed to assess the efficacy of clarithromycin, an antibiofilm agent, in patients with Kawasaki disease. METHODS AND RESULTS: We conducted an open‐label, multicenter...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Nanishi, Etsuro, Nishio, Hisanori, Takada, Hidetoshi, Yamamura, Kenichiro, Fukazawa, Mitsuharu, Furuno, Kenji, Mizuno, Yumi, Saigo, Kenjiro, Kadoya, Ryo, Ohbuchi, Noriko, Onoe, Yasuhiro, Yamashita, Hironori, Nakayama, Hideki, Hara, Takuya, Ohno, Takuro, Takahashi, Yasuhiko, Hatae, Ken, Harada, Tatsuo, Shimose, Takayuki, Kishimoto, Junji, Ohga, Shouichi, Hara, Toshiro
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5586277/
https://ncbi.nlm.nih.gov/pubmed/28684643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.005370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados